Does the DEA Investigate Medical Providers that Prescribe and Administer Ketamine.

Yes. The DEA investigates ketamine diversion through the same Diversion Control Division infrastructure that investigates opioid diversion, applying the same legal standards and the same investigative tools to the extent those tools are applicable to a Schedule III substance with the clinical profile of ketamine.

The scope of DEA ketamine investigations has expanded alongside the growth of the ketamine clinical practice market. As ketamine infusion clinics have proliferated and as the volume of ketamine prescribed and administered in clinical settings has increased substantially, the DEA's monitoring of ketamine distribution and the investigative resources directed at ketamine diversion have both increased. The practitioner or clinic that prescribes or administers ketamine in the current environment is operating in an environment where DEA oversight is real and active.

The Investigative Triggers for Ketamine Cases

DEA ketamine investigations are typically triggered by different mechanisms than opioid prescribing investigations, reflecting the different distribution channel through which ketamine reaches patients. Rather than PDMP outlier analysis, which is the primary opioid investigation trigger, ketamine investigations are more commonly triggered by controlled substance inventory discrepancies, facility inspection findings, theft reports, patient complaints, or referrals from other law enforcement agencies that have identified diverted ketamine in the illicit drug supply.

A ketamine clinic whose inventory records cannot reconcile ketamine purchases against documented clinical administrations has created the accounting discrepancy that a DEA inspection will identify. A clinic that has experienced a staff theft of ketamine and that failed to report it as required, or that reported it but whose records suggested the theft was occurring over an extended period without detection, has created the kind of record that investigations treat as evidence of inadequate security and oversight.

The Clinical Documentation Standard in Ketamine Cases

The clinical standard applied to ketamine investigations is the same usual course of professional practice standard applied to opioid investigations, assessed against the clinical guidelines and published evidence applicable to ketamine's specific therapeutic uses. A ketamine infusion clinic that administers ketamine to patients for treatment-resistant depression must document the clinical basis for the treatment, the patient's prior treatment history, the patient's informed consent, the administration protocol followed, the monitoring conducted during and after administration, and the clinical assessment of the treatment's effects.

The absence of that documentation, in a clinic whose ketamine administration volume is high, creates the same kind of clinical documentation gap that opioid cases present: a high volume of controlled substance use without the clinical record that would justify it. The government's medical expert in a ketamine case will apply the same methodology as in opioid cases, reviewing the clinical records against applicable standards and rendering an opinion about whether the administrations were clinically appropriate.

Veterinary Ketamine Investigations

The DEA also investigates ketamine diversion from veterinary sources, as discussed earlier in this series. Veterinary practices that maintain ketamine inventories with inadequate security controls, that fail to maintain accurate dispensing records, or that employ individuals who access ketamine for non-veterinary purposes are practices whose DEA registration subjects them to investigation. The veterinary channel is a significant source of diverted ketamine in the illicit market, and DEA veterinary inspections specifically address ketamine inventory management.

The DEA's investigation of ketamine practice is real, active, and applying the same legal standards as opioid investigation. The practitioner or clinic that assumes ketamine's Schedule III classification or its clinical novelty provides protection from DEA scrutiny has misjudged the enforcement environment. The protection comes from the same source as in opioid cases: the clinical record that demonstrates legitimate medical purpose, within the usual course of professional practice, documented with contemporaneous specificity.

Recent Enforcement Activity

DEA enforcement actions involving ketamine clinics and ketamine prescribing have increased as the market has grown. Investigations have addressed inventory management failures, prescribing to patients without adequate clinical evaluation, billing fraud where ketamine-related services were billed to federal programs without adequate documentation, and the diversion of ketamine from clinical settings into the recreational drug market. The legal theories in those cases track the same statutes as opioid cases: 21 U.S.C. 841 for distribution outside the usual course of professional practice and 18 U.S.C. 1347 for healthcare fraud where billing fraud is present.